Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An immune cell-selective interleukin 4 agonist

A B Shanafelt1, C P Forte, J J Kasper

  • 1Bayer Corporation, Pharmaceutical Division, Biotechnology, 800 Dwight Way, Berkeley, CA 94710, USA. Shanafelt.B@bayer.com

Proceedings of the National Academy of Sciences of the United States of America
|August 5, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.

Cell death and differentiation·2016
Same author

Correlation of postural balance and knee muscle strength in the sit-to-stand test among women with and without postmenopausal osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2013
Same author

How acoustic cavitation can improve adhesion.

Ultrasonics·2012
Same author

Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma.

Allergy·2009
Same author

Meniscectomy alters the dynamic deformational behavior and cumulative strain of tibial articular cartilage in knee joints subjected to cyclic loads.

Osteoarthritis and cartilage·2008
Same journal

Chemotactic self-organization captures the dynamics of mammalian hair follicle patterning.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Tomographic imaging of superconducting order using particle-hole interference.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inhibitory potential of autologous neutralizing antibodies sets quantitative limits on the rebound-competent HIV-1 reservoir.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inferring epidemiological parameters under an infectious phylogeography model with visitor dynamics.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Analytical modeling for suction cup designs for skin-interfaced wearable devices.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Improving cell-free metabolism through direct integration of artificial respiratory chains.

Proceedings of the National Academy of Sciences of the United States of America·2026
See all related articles

Researchers engineered a novel Interleukin-4 (IL-4) variant, IL-4/R121E, that selectively targets immune cells like T cells, sparing endothelial cells. This discovery offers potential for treating autoimmune diseases.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cytokine Research

Background:

  • Interleukin-4 (IL-4) is a pleiotropic cytokine with diverse cellular targets.
  • Distinct IL-4 receptor (IL-4R) complexes exist on different cell types: T cells utilize IL-4Ralpha/IL-2Rgamma (class I), while endothelial cells use IL-4Ralpha/IL-13Ralpha (class II).

Purpose of the Study:

  • To develop IL-4 variants with cell-type selectivity based on differential IL-4R expression.
  • To investigate the potential therapeutic applications of such selective IL-4 variants.

Main Methods:

  • Generation of IL-4 muteins by substituting regions interacting with IL-2Rgamma.
  • Evaluation of mutein activity in T cell and endothelial cell assays.
  • Receptor binding studies to confirm interaction profiles.

Related Experiment Videos

Main Results:

  • The IL-4/R121E mutein demonstrated complete biological selectivity for T cells, B cells, and monocytes.
  • IL-4/R121E showed no activity on endothelial cells.
  • Binding studies confirmed IL-4/R121E interacts with IL-2Rgamma but not IL-13Ralpha, acting as an antagonist for IL-4 on endothelial cells.

Conclusions:

  • IL-4/R121E exhibits a unique activity profile, selectively targeting immune cells.
  • The selective nature of IL-4/R121E suggests its potential utility in treating autoimmune diseases by modulating specific immune responses.